A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8+ T-cell-mediated anti-tumor immunity  by Song, Ying-Chyi et al.
Journal of Controlled Release 173 (2014) 158–165
Contents lists available at ScienceDirect
Journal of Controlled Release
j ourna l homepage: www.e lsev ie r .com/ locate / jconre lA novel emulsion-type adjuvant containing CpG oligodeoxynucleotides
enhances CD8+ T-cell-mediated anti-tumor immunityYing-Chyi Song a, Han-Yin Cheng a, Chih-Hsiang Leng a,b, Sheng-Kuo Chiang a, Chih-Wei Lin a, Pele Chong a,b,
Ming-Hsi Huang a,⁎, Shih-Jen Liu a,b,⁎⁎
a National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan
b Graduate Institute of Immunology, China Medical University, Taichung, Taiwan⁎ Corresponding author.
⁎⁎ Correspondence to: S.-J. Liu, National Institute of Infec
National Health Research Institutes, Miaoli, Taiwan.
E-mail addresses: huangminghsi@nhri.org.tw (M.-H. H
(S.-J. Liu).
0168-3659 © 2013 The Authors. Published by Elsevier B.V
http://dx.doi.org/10.1016/j.jconrel.2013.10.027a b s t r a c ta r t i c l e i n f oArticle history:
Received 15 August 2013
Accepted 21 October 2013
Available online 29 October 2013
Keywords:
Adjuvant
Immunotherapy
Human papillomavirus (HPV)
Cervical cancer
CpG oligodeoxynucleotidePELC is a novel emulsion-type adjuvant that contains the bioresorbable polymer poly (ethylene glycol)-block-
poly (lactide-co-ε-caprolactone) (PEG-b-PLACL), Span®85 and squalene. To investigate whether PELC is able to
enhance CTL responses of antigens for treating tumor, peptides or protein antigens derived from HPV16 E7
were formulated with PELC nanoparticles and CpG oligodeoxynucleotide. We identiﬁed that PELC formulation
could delay the release of antigens in vitro and in vivo. We assessed the immunogenicity of an H-2Db-restricted
CTL epitope RAHYNIVTF (RAH) formulated with PELC or PELC/CpG and investigated the ability of these formula-
tions to promote tumor regression. Following a single-dose subcutaneous injection in mice, we found that the
RAH peptide formulated with PELC/CpG (RAH/PELC/CpG) resulted in increased numbers of IFN-γ-secreting
cells and RAH-speciﬁc CD8+ T cells and an enhanced cytotoxic T cell response compared with RAH formulated
with PELC or CpG alone. The tumor-bearing mice received a single-dose injection of RAH/PELC/CpG, which in-
duced complete tumor regression. These results demonstrated that peptide antigen formulated with PELC/CpG
nanoparticles is feasible for cancer immunotherapy.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-SA license. 1. Introduction
Humanpapillomavirus (HPV) infection is themost common cause of
cervical cancer. Over 100 HPV types have been identiﬁed; some of the
types that have been detected in cervical cancer are called “high-risk”
HPV [1]. The four HPV types most frequently found among women
worldwide with cervical cancer are types 16, 18, 33 and 58. Currently,
there are two protein-based HPV vaccines (Cervarix® for types 16 and
18 and Gardasil® for types 6, 11, 16 and 18) used to prevent HPV infec-
tion and cervical intraepithelial neoplasia [2–7]. Both vaccines contain
the HPV capsid protein (L1), which can induce neutralizing antibodies
that block virus infection but cannot destroy virally infected or cancer
cells. However, the high cost of the HPV vaccines limits mass vaccina-
tion in developing countries. Therefore, the development of efﬁcient
therapeutic approaches for cervical cancer is still needed. The HPV E7tious Diseases and Vaccinology,
uang), levent@nhri.org.tw
. Open access under CC BY-NC-SA liceoncoprotein is highly conserved amongdifferent genotypes [8,9];more-
over, it is a tumor-speciﬁc and a tumor-rejection antigen. Therefore,
some studies have designed the E7 protein as the target for the develop-
ment of therapeutic vaccines for treating HPV16-associated cancer and
its precursor lesions [10–12]. In addition, the evolution of vaccine strat-
egies has seen a move from whole organisms to recombinant proteins,
with further development towards the most minimalist epitope possi-
ble. Nonetheless, a major challenge remains to turn poor immunogenic
epitopes into potent and effective vaccines.
In general, vaccines contain adjuvants to enhance the immunity
against the immunogens and to thereby make the vaccine more effec-
tive. Aluminum-based mineral salts are currently incorporated as adju-
vants in prophylactic HPV vaccines (Cervarix® and Gardasil®). These
adjuvants effectively induce protective antibody titers against virus
entry but do not induce Th1 responses or CTLs for killing HPV-infected
or cervical cancer cells [13]. To this end, many new adjuvant formula-
tions are being examined in various preclinical and clinical trials for
treating cervical cancer [14]. On the basis of their mechanisms of action,
adjuvants can be broadly divided into delivery systems and immuno-
potentiators [15,16]. The delivery systems (for example, liposomes
and MF59) may target antigens to the key cells and/or sites necessary
to colocalize antigens and immunopotentiators [17,18]. In our previous
study, we introduced a new delivery system adjuvant (PELC) for the de-
velopment of vaccines that was a water-in-oil-in-water nanoemulsion
composed of a bioresorbable polymer, Span®85, and squalene [19]. Innse. 
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(ethylene glycol)-block-poly (lactide-co-ε-caprolactone) (PEG-b-PLACL)
served as a hydrophilic emulsiﬁer, and Span®85 acted as a hydrophobic
emulsiﬁer to stabilize the water/squalene interface.We also showed that
a single-dose injection of the PELC nanoparticle-formulated inactivated
H5N1 virus vaccine in mice induced potent antigen-speciﬁc antibody ti-
ters [20].Moreover, emulsiﬁed PELC nanoparticles containing inactivated
an H5N1 virus and CpG (an immunostimulatory oligodeoxynucleotide
containing unmethylated cytosine–guanosine motifs) induced a cross-
protecting antibody response against a heterologous virus strain [21].
However, whether the peptide/protein formulated with the PELC nano-
particle can induce cytotoxic T lymphocyte responses still needs to be
investigated.
Immunopotentiators activate innate immunity directly (for example,
cytokines) or through pattern-recognition receptors (PRRs, such as
those for bacterial components). The Toll-like receptors (TLRs) are a
family of PRRs that are an important link between innate and adaptive
immunity. Some studies have shown that TLR ligands have adjuvant ac-
tivity and enhance antigen-speciﬁc antibody and cell-mediated immune
responses, especially when they are combined with delivery systems
that promote their uptake and delivery into antigen-presenting cells
[22–24]. For clinical studies, TLR9 is generally stimulated with synthetic
oligodeoxynucleotides containing one ormore unmethylated CpG dinu-
cleotides. In humans, CpG has been used as an adjuvant for infectious
disease vaccination [25,26] and in the development of cancer therapy
[27]. In a mouse model, CpG has also been shown to induce T helper 1
(Th1) immune responses, which are characterized by the production
of IFN-γ and the generation of IgG2a [28,29]. Moreover, a previous
study had demonstrated that different liposomes with CpG ODN signif-
icantly increased Th1-biased cytokines and augmented cell mediated
immune response [30].
For this article, we selected an H-2Db-restricted CTL epitope (amino
acids 49–57, RAHYNIVTF) (RAH) derived from the HPV 16 E7 protein or
the recombinant mutant E7 (rE7m) [31] as models to study the cellular
immune responses to the peptide/protein formulatedwith PELC orwith
a combination of PELC and CpG and to evaluate whether the candidate
vaccine formulations could be used as a tool for cancer immunotherapy.
We examined the cellular immune responses and the tumor regression
in mice that received a single injection of RAH peptides alone or of RAH
peptides formulated with PELC, CpG, or a PELC/CpG combination. This
studydemonstrated that peptide antigens formulatedwith both a deliv-
ery system (PELC) and an immunopotentiator (CpG) could induce
strong CTL responses against cervical cancer.
2. Materials and methods
2.1. Materials
The H-2Db-restricted CTL epitope (amino acids 49–57, RAHYNIVTF)
(RAH) derived from the HPV16 E7 protein was synthesized in-house by
the solid phasemethod using an automated peptide synthesizer, model
PS-3 from Protein Technologies, Inc. (Tucson, AZ, U.S.A.), employing the
ﬂuorenylmethoxycarbonyl (Fmoc) group forα-amino group protection.
The ﬁnal de-blocking step was carried out with Reagent K (amixture of
TFA/thioanisole/phenol/water/EDT). The crude peptide was recovered
by a precipitationmethodwith ether as the non-solvent and further pu-
riﬁed by reversed-phase HPLC using a gradient elution. Mass spectrom-
etry data were obtained from an Agilent 1100 Series LC/MSD high-
performance ion trap mass spectrometer to ensure that purity higher
than 90% was obtained. The peptide was dissolved in DMSO (Sigma,
MO, USA) at a stock concentration of 10 mg/ml. CpG ODN was synthe-
sized by Invitrogen Taiwan Ltd. and given as a 10 μg dose dissolved in
PBS or in the antigenic media. The CpG ODN sequence used was 5′-
TCC ATG ACG TTC CTG ACG TT-3′ with a phosphorothioate backbone.
The TC-1 cell line, a mouse epithelial cell line transformed with the on-
cogenes Ras and HPV16 E6 and E7, was a kind gift from Dr. T-C. Wu(Johns Hopkins University, USA). TC-1 cells were cultured in DMEM
(GIBCO-BRL, NY) supplemented with 10% heat-inactivated fetal bovine
serum (HyClone, Logan, Utah), penicillin (100 U/ml) and streptomycin
(100 μg/ml) (GIBCO-BRL, NY, USA). A complete RPMI-10 medium
contained RPMI-1640 supplemented with 10% (v/v) heat-inactivated
fetal calf serum, 25 mM HEPES (Biological industries, Beit Haemek,
Israel), penicillin (100 U/ml) and streptomycin (100 μg/ml).
2.2. The preparation of PELC
PELC is a squalene nanoemulsion stabilized by Span®85 (sorbitan
trioleate, Sigma-Aldrich, Steinheim, Germany) and PEG-b-PLACL, as
previously described [19,20,32]. Brieﬂy, 120 mg of PEG-b-PLACL,
0.8 ml of phosphate buffered saline (PBS), and 1.1 ml of an oily solution
consisting of squalene (Sigma-Aldrich, Steinheim, Germany) and
Span®85 (85/15, v/v) were emulsiﬁed using a Polytron®PT 3100 ho-
mogenizer (Kinematica AG, Switzerland) at 6000 rpm for 5 min. The
emulsiﬁed PELC formulation was stored at 4 °C until use. A PELC-
formulated vaccine was prepared for experiments by re-dispersing
200 mL of a stock emulsion into 1800 mL of a bulk vaccine and mixing
with a test tube rotator (Labinco LD-79, Netherlands) at 5 rpm at least
1 h before injection. The microscopic aspects of the emulsions were
monitoring with an optical microscope (Olympus DP70 Digital Micro-
scope Camera, Melville, NY, USA). Particle size distribution was deter-
mined by the laser light scattering technique. Peptide release
experiments were performed with the inverted dialysis tube method
[33]. Brieﬂy, RAH-containing formulations (50 μg per 50 μl) were ﬁrst
placed in a dialysis chamber (cut-off 0.2 μm), and then the device was
immersed in a 1.5 ml eppedorf containing 1 mL ddH2O and placed at
37 °C. At different time intervals, the RAH release was regularly deter-
mined by themicro bicinchoninic acid (BCA)method (MicroBCA™ pro-
tein assay kit; Thermo, IL, USA).
2.3. In vivo ﬂuorescence imaging
Alexa Fluor® 647-conjugated RAH peptide (RAH-Alexa 647,
absorption = 650 nm; ﬂuorescence emission = 668 nm) was pur-
chased from GeneDireX (Nevada, USA). C57BL/6 mice were subcutane-
ously injected with 50 μg of RAH-Alexa 647 combined with CpG
(10 μg), PELC (10%) or both. Before using Spectrum Imaging System,
micewere anesthetizedwith isoﬂurane at amaintenance concentration
of 2.5%, and oxygen pressurized at 4 kg/cm2 in conjunction with XGI-8
Anesthesia System. After treatment, in-life ﬂuorescence analysis was
performed at 6, 30, 48, 72, 144, 168, 240, 336 and 384 h by using a
Xenogen IVIS® Spectrum 200 Imaging System (Caliper Life Sciences,
USA). The ﬂuorescent measurement and region of interest (ROI) were
quantiﬁed and analyzed by using IVIS Living Image 4.0 software
package.
2.4. Animals
Female C57BL/6 mice, 6–12 weeks of age, were obtained from the
National Laboratory Animal Breeding and Research Center (Taipei,
Taiwan). All the animals were housed at the Animal Center of Na-
tional Health Research Institutes (NHRI) and maintained in accor-
dance with the institutional animal care protocol. All of the animal
studies were approved by the animal committee of the NHRI
(NHRI-IACUC-095-051-A).
2.5. The detection of peptide-speciﬁc CD8+ T cells
The C57BL/6 mice were immunized subcutaneously once with H-
2Db-restricted CTL peptides (RAH; 10 μg) mixed with or without
10 μg of murine CpG ODN (Invitrogen) in PELC (10%) adjuvant. After
one week, splenocytes were harvested, and the RAH-speciﬁc CD8+ T
cells were detected by tetramer staining using a PE-labeled RAH
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(eBioscience, CA, USA). The stained RAH-speciﬁc CD8+ T cells were an-
alyzed by ﬂow cytometry.
For the ELISPOT assay, spleens from the immunized mice were har-
vested and the response of IFN-γ-secreting cells was determined by
ELISPOT after 48 h of peptide or protein re-stimulation. Brieﬂy,
2 × 105 splenocytes were incubated with irrelevant peptides or RAH
peptides in an anti-IFN-γ-coated PVDF plate for 48 h. After the incuba-
tion, the cells were removed, and a biotinylated anti-IFN-γ antibody
(eBioscience, San Diego, CA, USA) was added to each well. The plates
were then incubated at 37 °C for 2 h. Following the addition of the
avidin-HRP reagent (eBioscience, CA, USA), the assay was developed
with a 3-amine-9-ethyl carbazole (AEC; Sigma-Aldrich, MO, USA) stain-
ing solution. The reaction was stopped after 4–6 min by placing the
plate under tap water. The spots were then counted using an ELISPOT
reader (Cellular Technology Ltd., Shaker Heights, OH, USA).2.6. In vivo cytolysis assay
The C57BL/6 mice were immunized subcutaneously once with RAH
(10 μg) mixed with or without 10 μg of murine CpG ODN in a PELC
(10%) adjuvant, and then after 7 days, CFSE-labeled target cells were
adoptively transferred into the mice. The target cells were prepared
from syngeneic splenocytes treated with a RBC lysis buffer (Biolegend)
for 2 min to remove red blood cells. The cells were divided into two
parts, one of which was pulsed with 5 μg/ml of RAH peptides for
30 min at 37 °C. After the splenocytes were washed in PBS, the cells
only (non-peptide) and RAH peptide-pulsed cells were labeled at ﬁnal
concentrations of 1 μM CFSE (Molecular Probes, Eugene, OR) or 10 μM
CFSE, respectively, for 15 min at 37 °C. The splenocytes were added to
an ice-cold complete RPMI medium to stop the CFSE labeling. The cells
only and RAH-pulsed splenocytes were re-suspended in PBS and
remixed at a ratio of 1:1. The CFSE-labeled cells (2 × 107 per mouse)
were adoptively transferred via tail vein injection into the immunized
mice. The experimental cellswere harvested 18 h after adoptive transfer
and analyzed using FACSCalibur (Becton Dickinson Immunocytometry
Systems, San Jose, CA). Two equations were used to determine the per-
centage of lysis. The adjustment factor (A) was calculated by dividing
the percentage of cells loaded without peptide by the percentage of
cells loaded with RAH peptide in naïve controls. For the percent lysis
equation, the average of the As from 4 naïve mice was calculated, and
the following equation was used: % Speciﬁc lysis = [(% non-peptide ×
A) − % RAH peptide] / (% non-peptide × A).2.7. Tumor regression study in mice
To assess the therapeutic value of the vaccines, tumors were ﬁrst
generated by injecting 2 × 105 TC-1 cells into the abdominal region of
themice, and seven days later, the mice were subcutaneously vaccinat-
ed in a separate abdominal region with the indicated dose of vaccine
formulated with PELC at 100 μl/dose. The tumor volume and tumor
free survival of the mice was monitored over a 50-day post-tumor im-
plantation period.2.8. Statistical analysis
The graphs and statistical analyses were performed using GraphPad
Prism version 5.02 (GraphPad Software, Inc.). Multiple comparisons of
the ﬂuorescent measurement between groups and time points were
calculated by using the ANOVAmodel followed by a Bonferroni posttest
on log10-transformed values. Comparison of T cell immune responses
between groupswas determined by amultiple comparison test. The dif-
ferences were considered signiﬁcant at P b 0.05.3. Results
3.1. The formulation of antigens with PELC
The preparation of the PELC-formulated nanoparticle as an adjuvant
follows a two-step manufacturing process, as shown in Fig. 1A. In the
ﬁrst step, the aqueous solution of PEG-b-PLACL and the oil phase of
squalene and Span®85 were pre-emulsiﬁed to form a stable and isotro-
pic emulsion dubbed PELC. The aqueous solutions of antigen (RAH) and/
or immunopotentiator (CpG) were mixed to form homogeneous parti-
cles in the second step. The size distribution of these particles wasmea-
suredwith amicroscope and a particle size analyzer. Two different sizes
were observed, relatively large particles of 1 μm and smaller ones of
200 nm (Fig. 1B). Notably, several studies have veriﬁed that small sol-
utes or nanoparticles (b50 nm) are internalized by antigen-presenting
cells (APCs) through macropinocytosis [34], whereas poly(lactide-co-
glycolide) microparticles (N500 nm) and MF59 oil-in-water emulsion
200 nm in size can be internalized APCs through phagocytosis without
speciﬁc recognition [34,35]. Here, PELC-formulated particles possess
proper sizes for APCs uptake to facilitate the induction of cell-
mediated immunity. To evaluate whether this type of formulation al-
lows the antigen or immunopotentiator to be controlled and slowly re-
leased, an in vitro release experiment was performed using RAH as a
model peptide. Fig. 1C shows the cumulative release of RAH from the
PELC formulation. In the case of RAH without an adjuvant, more than
90% of the loaded RAH was released into the aqueous solution within
48 h. However, the release of the PELC-formulated RAH occurred with
a signiﬁcant delay, and less than 30% of the RAH was released during
the same period of time (Fig. 1C). These data showed that an aqueous
solution of antigen, when formulated with PELC, forms homogeneous
particles that delay the release of antigen. This delaymay lessen the ex-
tent of degradation and, thereby, protect the antigen and facilitate its
expression.
3.2. PELC delay the release of antigen in vivo
To investigate the release rate of PELC-formulated peptide antigen
in vivo, the mice were immunized with various formulations that con-
tains RAH-Alexa 647 and in-life ﬂuorescence analysis was performed
at 0, 6, 30, 48, 72, 144, 168, 240, 336 and 384 h. After the injection, the
ﬂuorescence signal was clearly presented on the dorsum of mice at
0 h in each group. After 72 h, the ﬂuorescence signal dropped dramati-
cally in both RAH-Alexa 647 alone (RAH group) and RAH-Alexa 647
mixed with CpG (RAH/CpG group) (Fig. 2A). Data analysis from ROI
showed us that the ﬂuorescence signals had about a 75–80% decrement
at 30 h in the RAHandRAH/CpG groups (Fig. 2B). On the other hand, the
signiﬁcant amount of ﬂuorescence signals were still visible in the PELC
formulated groups (RAH/PELC and RAH/CpG/PELC) at 240 h (Fig. 2A,
B). Both in vitro and in vivo results demonstrated that the PELC emulsi-
ﬁed delivery system could serve as either carrier or vehicle to deliver bi-
ologically active agents (e.g., RAH peptide and CpG immunostimulatory
adjuvants) to immune cells in a targeted and prolonged manner, thus
effectively probing and manipulating the vaccine immunogenicity.
These data were also conﬁrmed in protein antigen (data not shown).
Herein, PELC nanoemulsion has a depot effect that provides a sustained
release proﬁle of peptide/protein antigens.
3.3. The RAH peptide formulated with PELC and/or CpG enhances speciﬁc
CD8+ T cells
As we demonstrated that PELC nanoemulsion could prolong the re-
lease of antigens, wewill identify the immune response of antigens after
formulation with PELC and combination with or without CpG. The im-
munogenicity of the RAH peptide antigen after formulation with PELC,
CpG or PELC/CpG was determined in the mice relative to the induction
of the tumor antigen-speciﬁc CD8+ T cell response. The RAH peptide
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subcutaneously into the C57BL/6 mice. After 7 days, splenocytes were
isolated from the immunized mice and re-stimulated in vitro in the
presence of RAH. Among the various formulations, we found that RAH
formulated with PELC/CpG (RAH/PELC/CpG) induced the highest num-
ber of RAH-speciﬁc CD8+ T cells (0.32%) after immunization (Fig. 3A).
However, there was no signiﬁcant induction of RAH-speciﬁc CD8+ T
cells in the immunization with the RAH peptide formulated with PELC
or CpG alone compared to the RAH in PBS formulation (Fig. 3A). To fur-
ther investigate the RAH-speciﬁc IFN-γ-secreting cells after immuniza-
tion, the splenocytes from vaccinated mice were re-stimulated with
RAH.We found that the number of speciﬁc IFN-γ-secreting cells was in-
creased by immunization with RAH/PELC/CpG compared with RAH,
RAH/PELC or RAH/CpG (Fig. 3B). Immunization with either RAH/PELC
or RAH/CpG also resulted in slightly increased IFN-γ-secreting cells
compared with RAH alone.
3.4. The RAH peptide formulated with PELC and CpG elicits a CTL response
We additionally sought to study the efﬁciency of different formula-
tions for inducing a speciﬁc CTL response. To this end, the CTL responses
were detected using the in vivo CTL assay. Brieﬂy, themice were immu-
nized with RAH mixed with or without CpG in a PELC adjuvant. Seven
days later, the immunized mice were adoptively transferred with
CFSE-labeled target cells for 18 h. The purpose of this assay is to evalu-
ate whether immunized mice can kill peptide-pulsed cells speciﬁcally.
Unvaccinated mice showed similar amounts of speciﬁc lysis as mice
vaccinated with RAH peptides alone; RAH/PELC-immunized mice ex-
hibited a mildly increased killing activity. In the presence of CpG ODN,
the RAH peptide or RAH/PELC could induce strong cytotoxic effects
(Fig. 4A). The percentages of speciﬁc lysis were 0.52, 0.26, 0.90, 14.69,
and 64.84% in the Control, RAH, RAH/PELC, RAH/CpG, and RAH/
PELC/CpG groups, respectively (Fig. 4B). This result indicates that the
PELC adjuvant combined with CpG synergistically elicits a CTL response
when used in a peptide vaccine.
3.5. The RAH peptide formulated with PELC and/or CpG induces an anti-
tumor effect
To determinewhether the higher CTL response reﬂected anti-tumor
activity in vivo, different RAH formulations were injected once 7 days
after tumor inoculation. We found that immunization with RAH/PELC
or RAH/CpG delayed the tumor growth, but the tumor totally regressed
in the group that had been immunized with RAH/PELC/CpG (Fig. 5A).
The mice in the PBS control or RAH alone groups all died before day
50 after tumor implantation. In contrast, the tumor-free survival rates
were 30%, 50% and 100% for the RAH/PELC, RAH/CpG and RAH/
PELC/CpG group, respectively (Fig. 5B). To extend the application of
this formulation, recombinantmutant E7 protein (rE7m)was formulat-
edwith PELC/CpG (rE7m/PELC/CpG) to immunize themice once. Signif-
icant CD8+ T cell response and tumor regression were observed after
administering rE7m/PELC/CpG compared to rE7m/PELC or rE7m/CpG
(Supplemental Fig. 1). Taken together, PELC combined with CpG adju-
vant in a peptide/protein vaccine provides a robust CTL response and
anti-tumor activity.Fig. 1. PELC-formulated peptide/protein vaccine. (A) The schematic representation of the
PELC-formulated peptide/protein vaccine preparation. The preparation of PELC-
adjuvanted peptide vaccine follows a two-step procedure that includes emulsiﬁcation and
dispersion. First, an aqueous solution containing PEG-b-PLACL and an oily phase consisting
of squalene and Span®85were homogenized to form a stable and isotropic emulsion, PELC.
Next, the pre-emulsiﬁed stockwas dispersed into a peptide/protein solution to form homo-
geneous nanoparticles in the second step. (B) Homogeneous ﬁne particles were observed
with an Olympus DP70 microscope and laser light scattering analysis. (C) Cumulative re-
lease of RAH peptide from the PELC formulation. RAH was formulated with or without
10% PELC (50 μg per 50 μl) and placed in a dialysis chamber in a eppendorf containing
1 ml ddH2O. RAH release was monitored by the MicroBCA method. The data are presented
as the mean+ SD of four samples.
Fig. 2. Release of PELC-formulated RAH-Alexa 647 in vivo. C57BL/6 mice were subcutane-
ously immunizedwith 50 μg of RAH-Alexa 647 combinedwith CpG (10 μg), PELC (10%) or
both. (A) In-life ﬂuorescence image was performed at different time course by using a
Xenogen IVIS® Spectrum 200 Imaging System. (B) The ﬂuorescent measurement and re-
gion of interest (ROI) were analyzed by using IVIS Living Image 4.0 software package.
Data are expressed as the mean + SEM of three animals per group. *P b 0.05 versus RAH.
Fig. 3. The RAH peptide formulated in PELC and CpG enhanced speciﬁc CD8+ T cells. Mice
were subcutaneously administered a single injection with PBS, RAH (10 μg), RAH formu-
lated in PELC (10%) (RAH/PELC), RAH admixed with CpG (10 μg) (RAH/CpG), or RAH for-
mulated in PELC and CpG (RAH/PELC/CpG). (A) After 7 days, splenocytes were stained
with a PE-conjugated RAH/MHC tetramer and FITC-labeled anti-CD8 antibody. The per-
centage of double-positive-staining cells relative to the total number of cells is indicated
within each panel. In the down panel of A, the results are expressed as the mean + SEM
of the percentage with double positive staining cells. (B) Splenocytes from immunized
mice were stimulated with the RAH peptide (1 μg) and examined for IFN-γ-secreting
cells with ELISPOT. Data are expressed as the mean + SEM of four animals per group.
*P b 0.05, **P b 0.01, ***P b 0.001.
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The use of synthetic peptides and proteins as vaccines is safe, but be-
cause of poor immunogenicity, adjuvants are critical for inducing pro-
tective immunity. Based on their effective mechanisms, adjuvants can
be divided into two types-antigen delivery systems and immuno-
potentiators. The induction of CTL responses using a peptide immuno-
gen is not easy in the absence of adjuvants. To induce CTLs for killing
cancer cells, the use of both an antigen delivery system and an
immunopotentiator might generate synergistic effects. In the present
study, we showed that using a synthetic peptide derived from HPV16
E7 or the recombinant mutant E7 (rE7m) as the immunogen could in-
duce a signiﬁcant anti-tumor effect in the presence of PELC and CpG.
These new formulations could be potentially therapeutic vaccines for
HPV-associated cancers.
4.1. The development of a W/O/W emulsion-type adjuvant (PELC) for
cancer immunotherapy
In theory, good antigen delivery systems are able to target antigen-
presenting cells, such as dendritic cells, efﬁciently or prolong antigen
presentation by preventing degradation. Antigen delivery systemsinclude emulsion-type adjuvants and particulate-type adjuvants. An
oil-in-water (O/W) emulsion-type adjuvant, MF59, has been used in
ﬂu vaccines, which has been shown to enhance antibody titers in an el-
derly population [36,37]. MF59 has the advantages of low oil content
and high injectability when performing vaccination. Regarding the
mechanisms of adjuvant action, MF59 possesses high efﬁciency to the
induction of an early and strong cytokine- and chemokine-rich environ-
ment at the site of injection, and the beneﬁcial of modulation of genes
involved in leukocyte migration and antigen presentation [38]. The E7
protein formulated in MF59 can generate CTL responses against E7-
expressing cells, but the anti-tumor effect in vivo has not been reported
[39]. In addition, the combination of polylactide co-glycolide polymer
(PLG) microparticles and MF59 induced CTL activity against HIV-1 p24
gag [40]. However, further studies ofMF59 as an adjuvant for cancer im-
munotherapy are limited. In contrast, thewater-in-oil (W/O) emulsion-
type adjuvant possesses dispersed antigenic media and continuous oily
phases. This type of adjuvant has been evaluated to ascertain the
innocuity of the vaccine and to achieve long-term protective immune
responses. However, conventional incomplete Freund's adjuvant (IFA)
causes extensive tissue inﬂammations at the injection site, so IFA is re-
stricted for research purposes to laboratory animals. UnlikeW/O/W ad-
juvant PELC, W/O adjuvant IFA generates long-lived depots in the
injection site that may lead to the trapping of tumor-speciﬁc CD8+ T
cells at the injection site instead of promoting an effective T cell re-
sponse at the tumor site as described in the literature [41]. The newgen-
eration of W/O adjuvant, MontanideTM ISA51 and ISA 720, has been
used in clinical studies of cancer immunotherapy. The long peptides
(23–45 amino acids) of HPV16 E6 and E7 formulated with ISA-51
Fig. 4. The RAH peptide formulated in PELC and CpG elicited a cytotoxic T cell response
in vivo. Naïve spleen cells were pulsed with or without 5 μg/ml of RAH and then were
stained with 10 μM CFSE or 1 μM of CFSE, respectively, for 15 min at 37 °C. Both types
of CFSE-labeled cells were injected into vaccinated mice, and after 18 h, the spleens
were collected and analyzed byﬂowcytometry. The following equationwas used to deter-
mine speciﬁc lysis: % Speciﬁc lysis = [(% non-peptide × A) − % RAH peptide] / (% non-
peptide × A). The experiment was repeated twice. Adjustment factor (A) = RAH
peptide/non-peptide from naïve controls. Data are expressed as the mean + SEM of
four animals per group. ***P b 0.001.
163Y.-C. Song et al. / Journal of Controlled Release 173 (2014) 158–165induced strong T cell responses in a phase I clinical trial [42]. In a further
evaluation of the therapeutic efﬁcacy of this formulation, HPV16-
positive women with high-grade vulvar intraepithelial neoplasia
were evaluated. Nine of twenty vaccinated patients showed complete
regression of all lesions and eradication of the virus [43,44]. These re-
sults showed that a peptide vaccine formulated with an emulsion-
type adjuvant could generate strong T cell responses against an
intraepithelial neoplasm. In the present study, PELC is a water-in-oil-
in-water (W/O/W) emulsion-type adjuvant that is generally recognized
as amore stable formulation [19]. It is probable thatW/O/Wnot only re-
served the depot effects intrinsic toW/O but also combined the antigen0
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Fig. 5. The RAH peptide formulated in PELC and CpG induced a large anti-tumor effect. TC-1 tu
RAH (10 μg), RAH formulated in PELC (10%) (RAH/PELC), RAH admixed with CpG (10 μg) (RA
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Tumor-free mice were deﬁned as having a non-enlarging mass b 100 mm3 in volume.presentation effects belonging to O/W. Another advantage of the PELC
formulation is that the pre-made emulsiﬁed PELC can simply be mixed
with antigen before injection. This approach could reduce the potential
for the incomplete emulsiﬁcation of the vaccine because of the variabil-
ity in individual compliance with procedures. Except for emulsion-type
adjuvants, the peptides or proteins of HPV16 E7 have been incorporated
into cationic liposomes, acid-degradable hydrogel particles [45] or
virosomes [46] to treat established tumor models and have been
shown to induce strong anti-tumor immunity [47–49]. These data dem-
onstrated that an antigen delivery system adjuvant could be used to
treat cancer. Here, our report showed that an easy-to-prepare PELC
emulsion that was formulated with peptide enhanced the therapeutic
effects of a cancer vaccine; in the presence of the TLR9 agonist (CpG)
and PELC, the peptide formulation synergistically elicited anti-tumor
immunity.
4.2. The incorporation of a TLR ligand in the PELC formulation enhanced
anti-tumor activity
In addition to the delivery systems used in a vaccine adjuvant, the
use of immunopotentiators as adjuvants also plays an important role
in increasing the vaccine efﬁcacy of immunogens, especially for peptides
with poor immunogenicity. Immunopotentiators include cytokines (IL-
2, GM-CSF) [50], chemokines (CCL5) [51], and innate receptor ligands
(TLR2, TLR4 and TLR9) [52–54]. Because the innate receptors recognize
conserved molecules expressed by a wide variety of infectious agents,
using innate receptor ligands as adjuvants maymimic the natural infec-
tion of microbes. Currently, innate receptor ligands are recognized to be
the new generation of adjuvants [55]. The TLR2 ligand, bacterial
lipopeptide, has been used to manufacture a Lyme disease vaccine
(LYMErix™) [56] and was licensed by the FDA in 1998 for general use.
The monophosphoryl lipid A (MPL) is a TLR4 ligand that has been com-
bined with aluminum salt (known as AS04) for hepatitis B vaccine
(FENDrix®) or HPV vaccine (Cervarix®) [57]. Most recently, the
unmethylated CpG motif in bacterial DNA has been identiﬁed as a
TLR9 ligand that stimulates endosomal TLR9 in antigen-presenting
cells (i.e., DC or macrophage). The synthetic oligodeoxynucleotide
(ODN) contains unmethylated cytosine–guanosine motifs (CpG) that
are usually composed of a phosphorothioate nucleotide. The preclinical
studies indicated that CpG has a good safety proﬁle and improves the ac-
tivity of vaccines targeting infectious diseases and cancer [58–64]. The0%
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164 Y.-C. Song et al. / Journal of Controlled Release 173 (2014) 158–165Pan-DR Th epitope has been conjugated to a peptide of HPV16 E7 and
formulated in a liposome and ISA-51 (called VacciMax®) with CpG
andwas shown to eradicate established tumors in vivo [65]. The combi-
nation therapy with cholera toxin-E7 fusion protein-pulsed DCs and the
local treatment of the tumor with CpG was required for the complete
eradication of cancer [66]. A new, low-dose, chemically stabilized form
of the E7SOs (E7SOx) that has been combined with CpG as an adjuvant
elicits a strong long-lasting protection against E7-expressed cancer [67].
Mansilla et al. reported that intravenous injection with the extracellular
domain of ﬁbronectin fused with E7, in combination with the TLR3 li-
gand, polyinosinic–polycytidylic acid (pIC), or CpG complexed with cat-
ionic lipids, was able to eradicate large established TC-1 tumors [68].
These promising results indicate that immunopotentiator CpG could
be very useful as an adjuvant in cervical cancer immunotherapy.
5. Conclusion
Our work presented here demonstrated that immunization of the
mice with the RAH peptide formulated with PELC or CpG alone induced
speciﬁc CD8+ T cell responses and an anti-tumor effect. However, im-
munization with RAH/PELC mildly inﬂuenced the killing activity, pre-
sumably due to the difference in the induction times of the CD8+ T
cell responses between immunization with RAH/PELC and RAH/CpG.
Moreover, PELC-formulated peptide vaccine in the presence of CpG syn-
ergistically elicited a CTL response and inhibited tumor growth. This for-
mulationmay attenuate peptide degradation to protect the antigen and
increase the half-life of the antigen. Taken together, we found that a
peptide/protein antigen formulatedwith the novel emulsion-type adju-
vant combinedwith an immune potentiator (TLR9 ligand) could induce
strong CTL responses against cancer. The combination of an antigen de-
livery system and immunopotentiators is a superb strategy for the de-
velopment of therapeutic tumor vaccines.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jconrel.2013.10.027.
Acknowledgments
This study was supported by grants from the National Health Re-
search Institutes (VC-100-PP-04 to S.-J. Liu and VC-100-PP-05 to M.-H.
Huang). The authors thank T-C- Wu at Johns Hopkins University for
the TC-1 cells.
References
[1] J.M. Walboomers, M.V. Jacobs, M.M. Manos, F.X. Bosch, J.A. Kummer, K.V. Shah, P.J.
Snijders, J. Peto, C.J. Meijer, N. Munoz, Human papilloma virus is a necessary cause
of invasive cervical cancer worldwide, J. Pathol. 189 (1999) 12–19.
[2] J. Paavonen, D. Jenkins, F.X. Bosch, P. Naud, J. Salmeron, C.M. Wheeler, S.N. Chow,
D.L. Apter, H.C. Kitchener, X. Castellsague, N.S. de Carvalho, S.R. Skinner, D.M.
Harper, J.A. Hedrick, U. Jaisamrarn, G.A. Limson, M. Dionne, W. Quint, B. Spiessens,
P. Peeters, F. Struyf, S.L. Wieting, M.O. Lehtinen, G. Dubin, Efﬁcacy of a prophylactic
adjuvanted bivalent L1 virus-like-particle vaccine against infection with human
papillomavirus types 16 and 18 in young women: an interim analysis of a phase
III double-blind, randomised controlled trial, Lancet 369 (2007) 2161–2170.
[3] J. Paavonen, P. Naud, J. Salmeron, C.M. Wheeler, S.N. Chow, D. Apter, H. Kitchener, X.
Castellsague, J.C. Teixeira, S.R. Skinner, J. Hedrick, U. Jaisamrarn, G. Limson, S. Garland,
A. Szarewski, B. Romanowski, F.Y. Aoki, T.F. Schwarz, W.A. Poppe, F.X. Bosch, D.
Jenkins, K. Hardt, T. Zahaf, D. Descamps, F. Struyf, M. Lehtinen, G. Dubin, Efﬁcacy of
human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infec-
tion and precancer caused by oncogenic HPV types (PATRICIA): ﬁnal analysis of a
double-blind, randomised study in young women, Lancet 374 (2009) 301–314.
[4] B. Romanowski, P.C. de Borba, P.S. Naud, C.M. Roteli-Martins, N.S. De Carvalho, J.C.
Teixeira, F. Aoki, B. Ramjattan, R.M. Shier, R. Somani, S. Barbier, M.M. Blatter, C.
Chambers, D. Ferris, S.A. Gall, F.A. Guerra, D.M. Harper, J.A. Hedrick, D.C. Henry, A.P.
Korn, R. Kroll, A.B. Moscicki, W.D. Rosenfeld, B.J. Sullivan, C.S. Thoming, S.K. Tyring,
C.M.Wheeler, G. Dubin, A. Schuind, T. Zahaf, M. Greenacre, A. Sgriobhadair, Sustained
efﬁcacy and immunogenicity of the human papillomavirus (HPV)-16/18
AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to
6.4 years, Lancet 374 (2009) 1975–1985.
[5] The FUTURE II Study Group, Quadrivalent vaccine against human papillomavirus to
prevent high-grade cervical lesions, N. Engl. J. Med. 356 (2007) 1915–1927.[6] S.M. Garland, M. Hernandez-Avila, C.M. Wheeler, G. Perez, D.M. Harper, S. Leodolter,
G.W. Tang, D.G. Ferris, M. Steben, J. Bryan, F.J. Taddeo, R. Railkar, M.T. Esser, H.L.
Sings, M. Nelson, J. Boslego, C. Sattler, E. Barr, L.A. Koutsky, Quadrivalent vaccine
against human papillomavirus to prevent anogenital diseases, N. Engl. J. Med. 356
(2007) 1928–1943.
[7] N. Munoz, S.K. Kjaer, K. Sigurdsson, O.E. Iversen, M. Hernandez-Avila, C.M. Wheeler,
G. Perez, D.R. Brown, L.A. Koutsky, E.H. Tay, P.J. Garcia, K.A. Ault, S.M. Garland, S.
Leodolter, S.E. Olsson, G.W. Tang, D.G. Ferris, J. Paavonen, M. Steben, F.X. Bosch, J.
Dillner, W.K. Huh, E.A. Joura, R.J. Kurman, S. Majewski, E.R. Myers, L.L. Villa, F.J.
Taddeo, C. Roberts, A. Tadesse, J.T. Bryan, L.C. Lupinacci, K.E. Giacoletti, H.L. Sings,
M.K. James, T.M. Hesley, E. Barr, R.M. Haupt, Impact of human papillomavirus
(HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young
women, J. Natl. Cancer Inst. 102 (2010) 325–339.
[8] S. Motoyama, C.A. Ladines-Llave, S. Luis Villanueva, T. Maruo, The role of human
papilloma virus in the molecular biology of cervical carcinogenesis, Kobe J. Med.
Sci. 50 (2004) 9–19.
[9] M.A. Stanley, M.R. Pett, N. Coleman, HPV: from infection to cancer, Biochem. Soc.
Trans. 35 (2007) 1456–1460.
[10] K. Hellner, K. Munger, Human papillomaviruses as therapeutic targets in human
cancer, J. Clin. Oncol. 29 (2011) 1785–1794.
[11] J.H. Su, A. Wu, E. Scotney, B. Ma, A. Monie, C.F. Hung, T.C. Wu, Immunotherapy for
cervical cancer: research status and clinical potential, BioDrugs 24 (2010) 109–129.
[12] S.H. van der Burg, C.J. Melief, Therapeutic vaccination against human papilloma
virus induced malignancies, Curr. Opin. Immunol. 23 (2011) 252–257.
[13] E.B. Lindblad, Aluminium adjuvants— in retrospect and prospect, Vaccine 22 (2004)
3658–3668.
[14] K. Lin, K. Doolan, C.F. Hung, T.C. Wu, Perspectives for preventive and therapeutic
HPV vaccines, J. Formos. Med. Assoc. 109 (2010) 4–24.
[15] A. Pashine, N.M. Valiante, J.B. Ulmer, Targeting the innate immune response with
improved vaccine adjuvants, Nat. Med. 11 (2005) S63–S68.
[16] M. Singh, D. O'Hagan, Advances in vaccine adjuvants, Nat. Biotechnol. 17 (1999)
1075–1081.
[17] D.T. O'Hagan, Recent developments in vaccine delivery systems, in: M.M. Levine, J.B.
Kaper, R. Rappuoli, M. Liu, M.F. Good (Eds.), New Generation Vaccines, 3th ed., Mar-
cel Dekker Inc., New York, 2004, pp. 259–270.
[18] E. Yuba, C. Kojima, A. Harada, Tana, S. Watarai, K. Kono, pH-Sensitive fusogenic
polymer-modiﬁed liposomes as a carrier of antigenic proteins for activation of cellu-
lar immunity, Biomaterials 31 (2010) 943–951.
[19] M.H.Huang, A.H. Chou, S.P. Lien,H.W. Chen, C.Y.Huang,W.W. Chen, P. Chong, S.J. Liu, C.H.
Leng, Formulationand immunological evaluationof novel vaccinedelivery systemsbased
on bioresorbable poly (ethylene glycol)-block-poly (lactide-co-epsilon-caprolactone), J.
Biomed. Mater. Res. B Appl. Biomater. 90 (2009) 832–841.
[20] M.H. Huang, C.Y. Huang, S.C. Lin, J.H. Chen, C.C. Ku, A.H. Chou, S.J. Liu, H.W. Chen, P.
Chong, C.H. Leng, Enhancement of potent antibody and T-cell responses by a
single-dose, novel nanoemulsion-formulated pandemic inﬂuenza vaccine, Microbes
Infect. 11 (2009) 654–660.
[21] M.H. Huang, S.C. Lin, C.H. Hsiao, H.J. Chao, H.R. Yang, C.C. Liao, P.W. Chuang, H.P. Wu,
C.Y. Huang, C.H. Leng, S.J. Liu, H.W. Chen, A.H. Chou, A.Y. Hu, P. Chong, Emulsiﬁed
nanoparticles containing inactivated inﬂuenza virus and CpG oligodeoxynucleotides
critically inﬂuences the host immune responses in mice, PLoS One 5 (2010) e12279.
[22] B.C. Baudner, V. Ronconi, D. Casini, M. Tortoli, J. Kazzaz, M. Singh, L.D. Hawkins, A.
Wack, D.T. O'Hagan, MF59 emulsion is an effective delivery system for a synthetic
TLR4 agonist (E6020), Pharm. Res. 26 (2009) 1477–1485.
[23] M. Singh, G. Ott, J. Kazzaz, M. Ugozzoli, M. Briones, J. Donnelly, D.T. O'Hagan, Cationic
microparticles are an effective delivery system for immune stimulatory cpG DNA,
Pharm. Res. 18 (2001) 1476–1479.
[24] J.S. Thomann, B. Heurtault, S. Weidner, M. Brayé, J. Beyrath, S. Fournel, F. Schuber, B.
Frisch, Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine
constructs incorporating TLR agonists andmannose receptor targeting, Biomaterials
32 (2011) 4574–4583.
[25] C.L. Cooper, H.L. Davis, M.L. Morris, S.M. Eﬂer, M.A. Adhami, A.M. Krieg, D.W. Cameron,
J. Heathcote, CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as
adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study, J.
Clin. Immunol. 24 (2004) 693–701.
[26] S.A. Halperin, G. Van Nest, B. Smith, S. Abtahi, H. Whiley, J.J. Eiden, A phase I study of
the safety and immunogenicity of recombinant hepatitis B surface antigen
co-administered with an immunostimulatory phosphorothioate oligonucleotide ad-
juvant, Vaccine 21 (2003) 2461–2467.
[27] A.M. Krieg, Development of TLR9 agonists for cancer therapy, J. Clin. Invest. 117
(2007) 1184–1194.
[28] R.S. Chu,O.S. Targoni, A.M.Krieg, P.V. Lehmann, C.V.Harding, CpGoligodeoxynucleotides
act as adjuvants that switch on T helper 1 (Th1) immunity, J. Exp. Med. 186 (1997)
1623–1631.
[29] R.D. Weeratna, M.J. McCluskie, Y. Xu, H.L. Davis, CpG DNA induces stronger immune
responses with less toxicity than other adjuvants, Vaccine 18 (2000) 1755–1762.
[30] E. Erikci, M. Gursel, I. Gursel, Differential immune activation following encapsulation
of immunostimulatory CpG oligodeoxynucleotide in nanoliposomes, Biomaterials
32 (2011) 1715–1723.
[31] C.Y. Huang, J.J. Chen, K.Y. Shen, L.S. Chang, Y.C. Yeh, I.H. Chen, P. Chong, S.J. Liu, C.H.
Leng, Recombinant lipidatedHPVE7 induces a Th-1-biased immune response andpro-
tective immunity against cervical cancer in amousemodel, PLoSOne 7 (2012) e40970.
[32] M.H. Huang, C.Y. Huang, S.P. Lien, S.Y. Siao, A.H. Chou, H.W. Chen, C.H. Leng, P.
Chong, Development of multi-phase emulsions based on bioresorbable polymers
and oily adjuvant, Pharm. Res. 26 (2009) 1856–1862.
[33] J. Aucouturier, L. Dupuis, V. Ganne, Adjuvants designed for veterinary and human
vaccines, Vaccine 19 (2001) 2666–2672.
165Y.-C. Song et al. / Journal of Controlled Release 173 (2014) 158–165[34] S.T. Reddy, M.A. Swartz, J.A. Hubbell, Targeting dendritic cells with biomaterials: de-
veloping the next generation of vaccines, Trends Immunol. 27 (2006) 573–579.
[35] A. Seubert, S. Calabro, L. Santini, B. Galli, A. Genovese, S. Valentini, S. Aprea, A.
Colaprico, U. D'Oro, M.M. Giuliani, M. Pallaoro, M. Pizza, D.T. O'Hagan, A. Wack, R.
Rappuoli, E. De Gregorio, Adjuvanticity of the oil-in-water emulsion MF59 is inde-
pendent of Nlrp3 inﬂammasome but requires the adaptor protein MyD88, Proc.
Natl. Acad. Sci. U. S. A. 108 (2011) 11169–11174.
[36] V. Parodi, D. de Florentiis, M. Martini, F. Ansaldi, Inactivated inﬂuenza vaccines: re-
cent progress and implications for the elderly, Drugs Aging 28 (2011) 93–106.
[37] W.E. Beyer, J.J. Nauta, A.M. Palache, K.M. Giezeman, A.D. Osterhaus, Immunogenicity
and safety of inactivated inﬂuenza vaccines in primed populations: a systematic lit-
erature review and meta-analysis, Vaccine 29 (2011) 5785–5792.
[38] F. Mosca, E. Tritto, A. Muzzi, E. Monaci, F. Bagnoli, C. Iavarone, D. O'Hagan, R.
Rappuoli, E. De Gregorio, Molecular and cellular signatures of human vaccine adju-
vants, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 10501–10506.
[39] X. Zhu,M. Tommasino, K. Vousden, E. Sadovnikava, R. Rappuoli, L. Crawford, M. Kast,
C.J. Melief, P.C. Beverley, H.J. Stauss, Both immunization with protein and recombi-
nant vaccinia virus can stimulate CTL speciﬁc for the E7 protein of human papilloma
virus 16 in H-2d mice, Scand. J. Immunol. 42 (1995) 557–563.
[40] D.T. O'Hagan, M. Ugozzoli, J. Barackman, M. Singh, J. Kazzaz, K. Higgins, T.C. Vancott,
G. Ott, Microparticles in MF59, a potent adjuvant combination for a recombinant
protein vaccine against HIV-1, Vaccine 18 (2000) 1793–1801.
[41] Y. Hailemichael, Z. Dai, N. Jaffarzad, Y. Ye, M.A. Medina, X.F. Huang, S.M.
Dorta-Estremera, N.R. Greeley, G. Nitti, W. Peng, C. Liu, Y. Lou, Z. Wang, W. Ma, B.
Rabinovich, K.S. Schluns, R.E. Davis, P. Hwu, W.W. Overwijk, Persistent antigen at
vaccination sites induces tumor-speciﬁc CD8+ T cell sequestration, dysfunction
and deletion, Nat. Med. 19 (2013) 465–472.
[42] G.G. Kenter, M.J. Welters, A.R. Valentijn, M.J. Lowik, D.M. Berends-van der Meer, A.P.
Vloon, J.W. Drijfhout, A.R. Wafelman, J. Oostendorp, G.J. Fleuren, R. Offringa, S.H. van
der Burg, C.J. Melief, Phase I immunotherapeutic trial with long peptides spanning
the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical
cancer patients shows low toxicity and robust immunogenicity, Clin. Cancer Res. 14
(2008) 169–177.
[43] G.G. Kenter, M.J. Welters, A.R. Valentijn, M.J. Lowik, D.M. Berends-van der Meer, A.P.
Vloon, F. Essahsah, L.M. Fathers, R. Offringa, J.W.Drijfhout, A.R.Wafelman, J. Oostendorp,
G.J. Fleuren, S.H. van der Burg, C.J. Melief, Vaccination against HPV-16 oncoproteins for
vulvar intraepithelial neoplasia, N. Engl. J. Med. 361 (2009) 1838–1847.
[44] C.J. Melief, Synthetic vaccine for the treatment of lesions caused by high risk human
papilloma virus, Cancer J. 17 (2011) 300–301.
[45] T.T. Beaudette, E.M. Bachelder, J.A. Cohen, A.C. Obermeyer, K.E. Broaders, J.M. Frechet,
E.S. Kang, I. Mende, W.W. Tseng, Davidson MG and Engleman EG: in vivo studies on
the effect of co-encapsulation of CpG DNA and antigen in acid-degradable micropar-
ticle vaccines, Mol. Pharm. 6 (2009) 1160–1169.
[46] A.R. Kammer, M. Amacker, S. Rasi, N. Westerfeld, C. Gremion, D. Neuhaus, R.
Zurbriggen, A new and versatile virosomal antigen delivery system to induce cellu-
lar and humoral immune responses, Vaccine 25 (2007) 7065–7074.
[47] Z. Cui, L. Huang, Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant
for protein-based vaccines: therapeutic effect against cervical cancer, Cancer
Immunol. Immunother. 54 (2005) 1180–1190.
[48] W. Chen,W. Yan, L. Huang, A simple but effective cancer vaccine consisting of an an-
tigen and a cationic lipid, Cancer Immunol. Immunother. 57 (2008) 517–530.
[49] W. Chen, L. Huang, Induction of cytotoxic T-lymphocytes and antitumor activity by a
liposomal lipopeptide vaccine, Mol. Pharm. 5 (2008) 464–471.
[50] M.G. Tovey, C. Lallemand, Adjuvant activity of cytokines, Methods Mol. Biol. 626
(2010) 287–309.
[51] N. Lapteva, X.F. Huang, CCL5 as an adjuvant for cancer immunotherapy, Expert.
Opin. Biol. Ther. 10 (2010) 725–733.[52] M.S. Duthie, H.P. Windish, C.B. Fox, S.G. Reed, Use of deﬁned TLR ligands as adju-
vants within human vaccines, Immunol. Rev. 239 (2011) 178–196.
[53] E. Celis, Toll-like receptor ligands energize peptide vaccines through multiple paths,
Cancer Res. 67 (2007) 7945–7947.
[54] J.T. Evans, C.W. Cluff, D.A. Johnson, M.J. Lacy, D.H. Persing, J.R. Baldridge, Enhance-
ment of antigen-speciﬁc immunity via the TLR4 ligands MPL adjuvant and
Ribi.529, Expert Rev. Vaccines 2 (2003) 219–229.
[55] F. Steinhagen, T. Kinjo, C. Bode, D.M. Klinman, TLR-based immune adjuvants, Vac-
cine 29 (2011) 3341–3355.
[56] A.C. Steere, V.K. Sikand, F. Meurice, D.L. Parenti, E. Fikrig, R.T. Schoen, J.
Nowakowski, C.H. Schmid, S. Laukamp, C. Buscarino, D.S. Krause, Vaccination
against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipo-
protein A with adjuvant. Lyme Disease Vaccine Study Group, N. Engl. J. Med. 339
(1998) 209–215.
[57] N. Garcon, L. Segal, F. Tavares, M. Van Mechelen, The safety evaluation of adju-
vants during vaccine development: the AS04 experience, Vaccine 29 (2011)
4453–4459.
[58] B. Burke, V.R. Gomez-Roman, Y. Lian, Y. Sun, E. Kan, J. Ulmer, I.K. Srivastava, S.W.
Barnett, Neutralizing antibody responses to subtype B and C adjuvanted HIV enve-
lope protein vaccination in rabbits, Virology 387 (2009) 147–156.
[59] D. Verthelyi, V.W. Wang, J.D. Lifson, D.M. Klinman, CpG oligodeoxynucleotides im-
prove the response to hepatitis B immunization in healthy and SIV-infected rhesus
macaques, AIDS 18 (2004) 1003–1008.
[60] G.J. Weiner, CpG oligodeoxynucleotide-based therapy of lymphoid malignancies,
Adv. Drug Deliv. Rev. 61 (2009) 263–267.
[61] A. Carpentier, F. Laigle-Donadey, S. Zohar, L. Capelle, A. Behin, A. Tibi, N.
Martin-Duverneuil, M. Sanson, L. Lacomblez, S. Taillibert, L. Puybasset, R. Van
Effenterre, J.Y. Delattre, A.F. Carpentier, Phase 1 trial of a CpG oligodeoxynucleotide
for patients with recurrent glioblastoma, Neuro. Oncol. 8 (2006) 60–66.
[62] P. Mukherjee, L.B. Pathangey, J.B. Bradley, T.L. Tinder, G.D. Basu, E.T. Akporiaye, S.J.
Gendler, MUC1-speciﬁc immune therapy generates a strong anti-tumor response
in a MUC1-tolerant colon cancer model, Vaccine 25 (2007) 1607–1618.
[63] G. Sen, Q. Chen, C.M. Snapper, Immunization of aged mice with a pneumococcal
conjugate vaccine combined with an unmethylated CpG-containing
oligodeoxynucleotide restores defective immunoglobulin G antipolysaccharide re-
sponses and speciﬁc CD4+−T-cell priming to young adult levels, Infect. Immun.
74 (2006) 2177–2186.
[64] C.C. Amaral, I.P. Garcia, G.F. Fernandes, S.R. Almeida, Z.P. Camargo, M.C. Souza, Adju-
vant effect of synthetic oligodeoxyribonucleotides (CpG-ODN) from the
Paracoccidioides brasiliensis gp43 gene on the Th2–Th1 immunomodulation of ex-
perimental paracoccidioidomycosis, Scand. J. Immunol. 62 (2005) 325–333.
[65] P. Daftarian, M. Mansour, A.C. Benoit, B. Pohajdak, D.W. Hoskin, R.G. Brown, W.M.
Kast, Eradication of established HPV 16-expressing tumors by a single administra-
tion of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide
in a water-in-oil emulsion, Vaccine 24 (2006) 5235–5244.
[66] A.G. Chandy, M. Nurkkala, A. Josefsson, K. Eriksson, Therapeutic dendritic cell vacci-
nation with Ag coupled to cholera toxin in combination with intratumoural CpG in-
jection leads to complete tumour eradication in mice bearing HPV 16 expressing
tumours, Vaccine 25 (2007) 6037–6046.
[67] M.L. Cerutti, L.G. Alonso, S. Tatti, G. de Prat-Gay, Long-lasting immunoprotective and
therapeutic effects of a hyperstable E7 oligomer based vaccine in a murine human
papillomavirus tumor model, Int. J. Cancer 130 (2012) 1813–1820.
[68] C. Mansilla, P. Berraondo, M. Durantez, M. Martinez, N. Casares, L. Arribillaga, F.
Rudilla, J. Fioravanti, T. Lozano, L. Villanueva, P. Sarobe, F. Borras, C. Leclerc, J.
Prieto, J.J. Lasarte, Eradication of large tumors expressing human papillomavirus
E7 protein by therapeutic vaccination with E7 fused to the extra domain a from ﬁ-
bronectin, Int. J. Cancer 131 (2012) 641–651.
